Research & Education

Management of Squamous Cell Carcinoma of the Lung

Thursday March 16, 2017 at 9:00PM EST - Recording Available

 

David R. Gandara, MD
Professor of Medicine
Program Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center

Name of Reviewer(s): 

               

Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 

 

Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 

 

Management of Squamous Cell Carcinoma of the Lung

Date of Activity:

 

03/16/2017

Faculty/Speaker(s)Disclosure:

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, and/or faculty’s et.l. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: David Gandara, MD

Speakers or Advisory Board , Honoraria and Support/Contract Research Grants with the following: Research Grants: AstraZeneca/Medi, BMS, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis Consultant: Ariad, AstraZeneca, Bayer, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant Helath, Lilly, Liquid Genomics, Merck, Mirati, Novartis Peregrine, Pfizer, Synta, Trovogene

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

    No

If yes, please list:

In this program we will examine the evolving therapeutic landscape for squamous cell non-small cell lung cancer (NSCLC) treatment.  The introduction of immune checkpoint inhibitors into treatment algorithms is the primary catalyst of new therapeutic options. We will review the completed and ongoing pivotal clinical trials that are contributing toward the development of new treatment paradigms for squamous NSCLC. We will also provide case examples that illustrate the decision-making process for practicing clinicians.

After viewing the program, attendees will be able:

  • illustrate the rapid evolution in the therapeutic landscape of advanced squamous lung cancer;
  • differentiate recently completed and ongoing clinical trials in advanced squamous lung cancer;
  • demonstrate how changes in treatment algorithms affect the decision-making process for practicing oncologists.

 This sixty minute program will be an interactive event, and there will be ample opportunity for attendees to e-mail questions and comments to the faculty for the purposes of fruitful exchange.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. 

In order to receive CME credit, attendees must fill out a program evaluation.

Financial/Commercial and Conflicts of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

DOWNLOAD RECORDING

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2017. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

Use the Time Zone Converter